The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Interest expense | -817,824 | - | - | 817,824 |
| Prepaid expenses | - | - | -363,768 | 164,218 |
| Due from related party | 0 | - | - | 0 |
| Other current liabilities | 0 | 0 | 0 | 0 |
| Amortization of debt discount | 1,583,890 | 5,998,239 | 2,021,209 | - |
| Initial recognition of forward purchase agreement liability | - | -95,062 | - | - |
| Issuance of commitment shares under eloc agreement | - | -275,000 | - | - |
| Loss on extinguishment of debt | 238,224 | 0 | 0 | -364,109 |
| Change in fair value of derivative liabilities and convertible notes | 251,807 | 3,470,145 | 775,062 | -289,401 |
| Interest capitalized | 9,008 | - | - | - |
| Stock based compensation | 13,406 | 0 | 0 | 0 |
| Prepaid expenses and other current assets | 835,047 | -174,254 | - | - |
| Inventories | 116,814 | 217,723 | 35,437 | - |
| Accounts payable | -139,535 | -46,526 | -1,318,670 | -80,386 |
| Accrued expenses | -316,955 | 781,667 | 280,780 | -95,816 |
| Net loss | -3,222,892 | -4,707,734 | -1,850,493 | -1,981,293 |
| Net cash flows used in operating activities | -3,038,522 | -927,841 | -1,103,809 | -1,140,310 |
| Proceeds from recapitalization | 0 | 0 | -1 | 0 |
| Proceeds from issuance of convertible notes | 0 | 0 | 7,250,000 | 0 |
| Repayment of convertible notes | - | 0 | 3,032,645 | - |
| Repayment of subscription agreement loan | - | - | 483,474 | - |
| Transaction costs paid in connection with convertible notes | - | 0 | 907,499 | - |
| Proceeds from notes payable - related party | 0 | 0 | 0 | 0 |
| Issuance of series a convertible preferred stock | 8,951,119 | - | - | 0 |
| Proceeds from debenture | 2,000,000 | - | - | - |
| Repayment of debenture | 2,173,913 | - | - | - |
| Repayment of notes payable related party | 885,564 | 500,000 | -19,466 | 0 |
| Net cash flows provided by financing activities | 7,891,642 | -16,526 | 2,845,847 | 0 |
| Net change in cash | 4,853,120 | - | - | - |
| Net change in cash | 4,853,120 | -944,367 | 1,742,038 | -1,140,310 |
| Cash, beginning of the year | 1,003,904 | 1,948,271 | 3,633 | - |
| Cash, end of the quarter | 5,857,024 | 1,003,904 | 1,948,271 | - |
Aspire Biopharma Holdings, Inc. (ASBPW)
Aspire Biopharma Holdings, Inc. (ASBPW)